Cortisol in schizophrenia: No association with tobacco smoking, clinical symptoms or antipsychotic medication
Cigarette smoking is associated with higher cortisol levels in healthy subjects. In schizophrenia this relationship is not clear. There are divergent results on the association between cortisol with smoking, clinical symptoms and medication in schizophrenia. This study evaluated this association in...
Gespeichert in:
Veröffentlicht in: | Progress in neuro-psychopharmacology & biological psychiatry 2017-07, Vol.77, p.228-235 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 235 |
---|---|
container_issue | |
container_start_page | 228 |
container_title | Progress in neuro-psychopharmacology & biological psychiatry |
container_volume | 77 |
creator | Nedic Erjavec, Gordana Uzun, Suzana Nikolac Perkovic, Matea Kozumplik, Oliver Svob Strac, Dubravka Mimica, Ninoslav Hirasawa-Fujita, Mika Domino, Edward F. Pivac, Nela |
description | Cigarette smoking is associated with higher cortisol levels in healthy subjects. In schizophrenia this relationship is not clear. There are divergent results on the association between cortisol with smoking, clinical symptoms and medication in schizophrenia. This study evaluated this association in 196 Caucasian inpatients with schizophrenia (51.30±26.68years old), subdivided into 123 smokers and 73 non-smokers. Basal salivary cortisol levels were measured twice, at 08.00 and 09.00AM, 90–120min after awakening. The effect of smoking on cortisol was evaluated according to current smoking status, the number of cigarettes/day and the nicotine addiction intensity. The influence of clinical symptoms and/or antipsychotic medication on cortisol was determined using the Positive and Negative Syndrome Scale (PANSS), and chlorpromazine equivalent doses.
Non-smokers were older, received lower doses of antipsychotics, had higher PANSS scores, and had longer duration of illness than smokers.
Salivary cortisol was similar in schizophrenic patients subdivided according to the smoking status, the number of cigarettes/day and nicotine addiction intensity. No significant correlation was found between salivary cortisol and PANSS scores, chlorpromazine equivalent doses, age of onset or the duration of illness.
The findings revealed no association between salivary cortisol and smoking, nicotine addiction intensity, or clinical symptoms. Our preliminary data showed no correlation between salivary cortisol and chlorpromazine equivalent doses and/or antipsychotic medication. Our findings suggest that smoking does not affect the cortisol response in schizophrenic patients as it has been shown in healthy individuals. Future studies should investigate a possible desensitization of the stress system to smoking.
•Saliva cortisol was not associated with smoking in schizophrenia.•Saliva cortisol did not differ after the first cigarette smoked that day in smokers.•Saliva cortisol was not related to the intensity of nicotine addiction in smokers.•Saliva cortisol was not correlated with various clinical symptoms of schizophrenia.•Saliva cortisol did not differ in patients treated with different antipsychotics. |
doi_str_mv | 10.1016/j.pnpbp.2017.04.032 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1894521068</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0278584616304675</els_id><sourcerecordid>1894521068</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-c1011da18fc698b4a09ad4c13a6014a2401272222f9445470d5ca1cd0bfc9a7c3</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi0EokvhFyBVPnJgw9hxvipxqFZ8SRVc2rPlTJzuLImd2l7Q8uvxdluOzMUj65kZvQ9jbwUUAkT9YVcsbumXQoJoClAFlPIZW4m2addKivo5W4HMfdWq-oy9inEHAKKE8iU7k_lPyEqu2LzxIVH0EyfHI27pj1-2wToyl_y75yZGj2QSecd_U9ry5HuD6Hmc_U9yd-85TuQIzcTjYV6SnyP3gRuXaIkH3PpEyGc7ZOK44zV7MZop2jeP7zm7_fzpZvN1ff3jy7fN1fUaFai0xpxPDEa0I9Zd2ysDnRkUitLUIJSRCoRsZK6xU6pSDQwVGoED9CN2psHynL077V2Cv9_bmPRMEe00GWf9PmrRdqqSAuo2o-UJxeBjDHbUS6DZhIMWoI-e9U4_eNZHzxqUzp7z1MXjgX2f4_2beRKbgY8nwOaYv8gGHZGsw6wiWEx68PTfA38Bxr2Rgg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1894521068</pqid></control><display><type>article</type><title>Cortisol in schizophrenia: No association with tobacco smoking, clinical symptoms or antipsychotic medication</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Nedic Erjavec, Gordana ; Uzun, Suzana ; Nikolac Perkovic, Matea ; Kozumplik, Oliver ; Svob Strac, Dubravka ; Mimica, Ninoslav ; Hirasawa-Fujita, Mika ; Domino, Edward F. ; Pivac, Nela</creator><creatorcontrib>Nedic Erjavec, Gordana ; Uzun, Suzana ; Nikolac Perkovic, Matea ; Kozumplik, Oliver ; Svob Strac, Dubravka ; Mimica, Ninoslav ; Hirasawa-Fujita, Mika ; Domino, Edward F. ; Pivac, Nela</creatorcontrib><description>Cigarette smoking is associated with higher cortisol levels in healthy subjects. In schizophrenia this relationship is not clear. There are divergent results on the association between cortisol with smoking, clinical symptoms and medication in schizophrenia. This study evaluated this association in 196 Caucasian inpatients with schizophrenia (51.30±26.68years old), subdivided into 123 smokers and 73 non-smokers. Basal salivary cortisol levels were measured twice, at 08.00 and 09.00AM, 90–120min after awakening. The effect of smoking on cortisol was evaluated according to current smoking status, the number of cigarettes/day and the nicotine addiction intensity. The influence of clinical symptoms and/or antipsychotic medication on cortisol was determined using the Positive and Negative Syndrome Scale (PANSS), and chlorpromazine equivalent doses.
Non-smokers were older, received lower doses of antipsychotics, had higher PANSS scores, and had longer duration of illness than smokers.
Salivary cortisol was similar in schizophrenic patients subdivided according to the smoking status, the number of cigarettes/day and nicotine addiction intensity. No significant correlation was found between salivary cortisol and PANSS scores, chlorpromazine equivalent doses, age of onset or the duration of illness.
The findings revealed no association between salivary cortisol and smoking, nicotine addiction intensity, or clinical symptoms. Our preliminary data showed no correlation between salivary cortisol and chlorpromazine equivalent doses and/or antipsychotic medication. Our findings suggest that smoking does not affect the cortisol response in schizophrenic patients as it has been shown in healthy individuals. Future studies should investigate a possible desensitization of the stress system to smoking.
•Saliva cortisol was not associated with smoking in schizophrenia.•Saliva cortisol did not differ after the first cigarette smoked that day in smokers.•Saliva cortisol was not related to the intensity of nicotine addiction in smokers.•Saliva cortisol was not correlated with various clinical symptoms of schizophrenia.•Saliva cortisol did not differ in patients treated with different antipsychotics.</description><identifier>ISSN: 0278-5846</identifier><identifier>EISSN: 1878-4216</identifier><identifier>DOI: 10.1016/j.pnpbp.2017.04.032</identifier><identifier>PMID: 28461252</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Adult ; Antipsychotic Agents - therapeutic use ; Antipsychotic medication ; Case-Control Studies ; Caucasians ; Chlorpromazine equivalent doses ; Cigarette smoking ; Female ; Humans ; Hydrocortisone - metabolism ; Male ; Middle Aged ; Nicotine addiction ; Saliva - metabolism ; Salivary cortisol ; Schizophrenia ; Schizophrenia - diagnosis ; Schizophrenia - drug therapy ; Schizophrenia - metabolism ; Schizophrenia symptoms ; Smoking - metabolism</subject><ispartof>Progress in neuro-psychopharmacology & biological psychiatry, 2017-07, Vol.77, p.228-235</ispartof><rights>2017</rights><rights>Copyright © 2017. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-c1011da18fc698b4a09ad4c13a6014a2401272222f9445470d5ca1cd0bfc9a7c3</citedby><cites>FETCH-LOGICAL-c404t-c1011da18fc698b4a09ad4c13a6014a2401272222f9445470d5ca1cd0bfc9a7c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.pnpbp.2017.04.032$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28461252$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nedic Erjavec, Gordana</creatorcontrib><creatorcontrib>Uzun, Suzana</creatorcontrib><creatorcontrib>Nikolac Perkovic, Matea</creatorcontrib><creatorcontrib>Kozumplik, Oliver</creatorcontrib><creatorcontrib>Svob Strac, Dubravka</creatorcontrib><creatorcontrib>Mimica, Ninoslav</creatorcontrib><creatorcontrib>Hirasawa-Fujita, Mika</creatorcontrib><creatorcontrib>Domino, Edward F.</creatorcontrib><creatorcontrib>Pivac, Nela</creatorcontrib><title>Cortisol in schizophrenia: No association with tobacco smoking, clinical symptoms or antipsychotic medication</title><title>Progress in neuro-psychopharmacology & biological psychiatry</title><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><description>Cigarette smoking is associated with higher cortisol levels in healthy subjects. In schizophrenia this relationship is not clear. There are divergent results on the association between cortisol with smoking, clinical symptoms and medication in schizophrenia. This study evaluated this association in 196 Caucasian inpatients with schizophrenia (51.30±26.68years old), subdivided into 123 smokers and 73 non-smokers. Basal salivary cortisol levels were measured twice, at 08.00 and 09.00AM, 90–120min after awakening. The effect of smoking on cortisol was evaluated according to current smoking status, the number of cigarettes/day and the nicotine addiction intensity. The influence of clinical symptoms and/or antipsychotic medication on cortisol was determined using the Positive and Negative Syndrome Scale (PANSS), and chlorpromazine equivalent doses.
Non-smokers were older, received lower doses of antipsychotics, had higher PANSS scores, and had longer duration of illness than smokers.
Salivary cortisol was similar in schizophrenic patients subdivided according to the smoking status, the number of cigarettes/day and nicotine addiction intensity. No significant correlation was found between salivary cortisol and PANSS scores, chlorpromazine equivalent doses, age of onset or the duration of illness.
The findings revealed no association between salivary cortisol and smoking, nicotine addiction intensity, or clinical symptoms. Our preliminary data showed no correlation between salivary cortisol and chlorpromazine equivalent doses and/or antipsychotic medication. Our findings suggest that smoking does not affect the cortisol response in schizophrenic patients as it has been shown in healthy individuals. Future studies should investigate a possible desensitization of the stress system to smoking.
•Saliva cortisol was not associated with smoking in schizophrenia.•Saliva cortisol did not differ after the first cigarette smoked that day in smokers.•Saliva cortisol was not related to the intensity of nicotine addiction in smokers.•Saliva cortisol was not correlated with various clinical symptoms of schizophrenia.•Saliva cortisol did not differ in patients treated with different antipsychotics.</description><subject>Adult</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Antipsychotic medication</subject><subject>Case-Control Studies</subject><subject>Caucasians</subject><subject>Chlorpromazine equivalent doses</subject><subject>Cigarette smoking</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrocortisone - metabolism</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nicotine addiction</subject><subject>Saliva - metabolism</subject><subject>Salivary cortisol</subject><subject>Schizophrenia</subject><subject>Schizophrenia - diagnosis</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - metabolism</subject><subject>Schizophrenia symptoms</subject><subject>Smoking - metabolism</subject><issn>0278-5846</issn><issn>1878-4216</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAQhi0EokvhFyBVPnJgw9hxvipxqFZ8SRVc2rPlTJzuLImd2l7Q8uvxdluOzMUj65kZvQ9jbwUUAkT9YVcsbumXQoJoClAFlPIZW4m2addKivo5W4HMfdWq-oy9inEHAKKE8iU7k_lPyEqu2LzxIVH0EyfHI27pj1-2wToyl_y75yZGj2QSecd_U9ry5HuD6Hmc_U9yd-85TuQIzcTjYV6SnyP3gRuXaIkH3PpEyGc7ZOK44zV7MZop2jeP7zm7_fzpZvN1ff3jy7fN1fUaFai0xpxPDEa0I9Zd2ysDnRkUitLUIJSRCoRsZK6xU6pSDQwVGoED9CN2psHynL077V2Cv9_bmPRMEe00GWf9PmrRdqqSAuo2o-UJxeBjDHbUS6DZhIMWoI-e9U4_eNZHzxqUzp7z1MXjgX2f4_2beRKbgY8nwOaYv8gGHZGsw6wiWEx68PTfA38Bxr2Rgg</recordid><startdate>20170703</startdate><enddate>20170703</enddate><creator>Nedic Erjavec, Gordana</creator><creator>Uzun, Suzana</creator><creator>Nikolac Perkovic, Matea</creator><creator>Kozumplik, Oliver</creator><creator>Svob Strac, Dubravka</creator><creator>Mimica, Ninoslav</creator><creator>Hirasawa-Fujita, Mika</creator><creator>Domino, Edward F.</creator><creator>Pivac, Nela</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170703</creationdate><title>Cortisol in schizophrenia: No association with tobacco smoking, clinical symptoms or antipsychotic medication</title><author>Nedic Erjavec, Gordana ; Uzun, Suzana ; Nikolac Perkovic, Matea ; Kozumplik, Oliver ; Svob Strac, Dubravka ; Mimica, Ninoslav ; Hirasawa-Fujita, Mika ; Domino, Edward F. ; Pivac, Nela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-c1011da18fc698b4a09ad4c13a6014a2401272222f9445470d5ca1cd0bfc9a7c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Antipsychotic medication</topic><topic>Case-Control Studies</topic><topic>Caucasians</topic><topic>Chlorpromazine equivalent doses</topic><topic>Cigarette smoking</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrocortisone - metabolism</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nicotine addiction</topic><topic>Saliva - metabolism</topic><topic>Salivary cortisol</topic><topic>Schizophrenia</topic><topic>Schizophrenia - diagnosis</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - metabolism</topic><topic>Schizophrenia symptoms</topic><topic>Smoking - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nedic Erjavec, Gordana</creatorcontrib><creatorcontrib>Uzun, Suzana</creatorcontrib><creatorcontrib>Nikolac Perkovic, Matea</creatorcontrib><creatorcontrib>Kozumplik, Oliver</creatorcontrib><creatorcontrib>Svob Strac, Dubravka</creatorcontrib><creatorcontrib>Mimica, Ninoslav</creatorcontrib><creatorcontrib>Hirasawa-Fujita, Mika</creatorcontrib><creatorcontrib>Domino, Edward F.</creatorcontrib><creatorcontrib>Pivac, Nela</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nedic Erjavec, Gordana</au><au>Uzun, Suzana</au><au>Nikolac Perkovic, Matea</au><au>Kozumplik, Oliver</au><au>Svob Strac, Dubravka</au><au>Mimica, Ninoslav</au><au>Hirasawa-Fujita, Mika</au><au>Domino, Edward F.</au><au>Pivac, Nela</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cortisol in schizophrenia: No association with tobacco smoking, clinical symptoms or antipsychotic medication</atitle><jtitle>Progress in neuro-psychopharmacology & biological psychiatry</jtitle><addtitle>Prog Neuropsychopharmacol Biol Psychiatry</addtitle><date>2017-07-03</date><risdate>2017</risdate><volume>77</volume><spage>228</spage><epage>235</epage><pages>228-235</pages><issn>0278-5846</issn><eissn>1878-4216</eissn><abstract>Cigarette smoking is associated with higher cortisol levels in healthy subjects. In schizophrenia this relationship is not clear. There are divergent results on the association between cortisol with smoking, clinical symptoms and medication in schizophrenia. This study evaluated this association in 196 Caucasian inpatients with schizophrenia (51.30±26.68years old), subdivided into 123 smokers and 73 non-smokers. Basal salivary cortisol levels were measured twice, at 08.00 and 09.00AM, 90–120min after awakening. The effect of smoking on cortisol was evaluated according to current smoking status, the number of cigarettes/day and the nicotine addiction intensity. The influence of clinical symptoms and/or antipsychotic medication on cortisol was determined using the Positive and Negative Syndrome Scale (PANSS), and chlorpromazine equivalent doses.
Non-smokers were older, received lower doses of antipsychotics, had higher PANSS scores, and had longer duration of illness than smokers.
Salivary cortisol was similar in schizophrenic patients subdivided according to the smoking status, the number of cigarettes/day and nicotine addiction intensity. No significant correlation was found between salivary cortisol and PANSS scores, chlorpromazine equivalent doses, age of onset or the duration of illness.
The findings revealed no association between salivary cortisol and smoking, nicotine addiction intensity, or clinical symptoms. Our preliminary data showed no correlation between salivary cortisol and chlorpromazine equivalent doses and/or antipsychotic medication. Our findings suggest that smoking does not affect the cortisol response in schizophrenic patients as it has been shown in healthy individuals. Future studies should investigate a possible desensitization of the stress system to smoking.
•Saliva cortisol was not associated with smoking in schizophrenia.•Saliva cortisol did not differ after the first cigarette smoked that day in smokers.•Saliva cortisol was not related to the intensity of nicotine addiction in smokers.•Saliva cortisol was not correlated with various clinical symptoms of schizophrenia.•Saliva cortisol did not differ in patients treated with different antipsychotics.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>28461252</pmid><doi>10.1016/j.pnpbp.2017.04.032</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0278-5846 |
ispartof | Progress in neuro-psychopharmacology & biological psychiatry, 2017-07, Vol.77, p.228-235 |
issn | 0278-5846 1878-4216 |
language | eng |
recordid | cdi_proquest_miscellaneous_1894521068 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Adult Antipsychotic Agents - therapeutic use Antipsychotic medication Case-Control Studies Caucasians Chlorpromazine equivalent doses Cigarette smoking Female Humans Hydrocortisone - metabolism Male Middle Aged Nicotine addiction Saliva - metabolism Salivary cortisol Schizophrenia Schizophrenia - diagnosis Schizophrenia - drug therapy Schizophrenia - metabolism Schizophrenia symptoms Smoking - metabolism |
title | Cortisol in schizophrenia: No association with tobacco smoking, clinical symptoms or antipsychotic medication |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T19%3A58%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cortisol%20in%20schizophrenia:%20No%20association%20with%20tobacco%20smoking,%20clinical%20symptoms%20or%20antipsychotic%20medication&rft.jtitle=Progress%20in%20neuro-psychopharmacology%20&%20biological%20psychiatry&rft.au=Nedic%20Erjavec,%20Gordana&rft.date=2017-07-03&rft.volume=77&rft.spage=228&rft.epage=235&rft.pages=228-235&rft.issn=0278-5846&rft.eissn=1878-4216&rft_id=info:doi/10.1016/j.pnpbp.2017.04.032&rft_dat=%3Cproquest_cross%3E1894521068%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1894521068&rft_id=info:pmid/28461252&rft_els_id=S0278584616304675&rfr_iscdi=true |